Identification of lncRNAs associated with uterine corpus endometrial cancer prognosis based on the competing endogenous RNA network.

Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE

Original Publication: [Australia] : Ivyspring International Publisher, c2004-

RNA, Long Noncoding*/genetics ; RNA, Long Noncoding*/metabolism ; MicroRNAs*/metabolism ; Endometrial Neoplasms*/diagnosis ; Endometrial Neoplasms*/genetics; Humans ; Female ; Gene Regulatory Networks/genetics ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Prognosis ; Biomarkers, Tumor/genetics ; Gene Expression Regulation, Neoplastic

Uterine Corpus Endometrial Carcinoma (UCEC) is one of the major malignant tumors of the female reproductive system. However, there are limitations in the currently available diagnostic approaches for UCEC. Long non-coding RNAs (lncRNAs) play important roles in regulating biological processes as competitive endogenous RNA (ceRNA) in tumors. To study the potential of lncRNAs as non-invasive diagnostic tumor markers, RNA-sequencing dataset of UCEC patients from The Cancer Genome Atlas was used to identify differentially expressed genes. A lncRNA-miRNA-mRNA ceRNA network was constructed by differentially expressed lncRNAs, miRNAs and miRNAs. Pathway enrichment and functional analysis for the mRNAs in the constructed ceRNA network provide the direction of future research for UCEC by demonstrating the most affected processes and pathways. Seven potential lncRNA biomarkers (C20orf56, LOC100144604, LOC100190940, LOC151534, LOC727677, FLJ35390, LOC158572) were validated in UCEC patients by quantitative real-time PCR. Notably, LOC100190940 and LOC158572 were identified as novel RNA molecules with unknown functions. Receiver operating characteristic (ROC) curve analysis demonstrated that the combined 7 lncRNAs had a high diagnostic value for UCEC patients with area under curve (AUC) of 0.941 (95% CI: 0.875-0.947). Our study highlights the potential of the validated 7 lncRNAs panel as diagnostic biomarkers in UCEC, providing new insights into the UCEC pathogenesis.
Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
(© The author(s).)

Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145)
Biomed Res Int. 2018 Feb 21;2018:7924153. (PMID: 29682556)
N Engl J Med. 2012 Mar 8;366(10):883-892. (PMID: 22397650)
Oxid Med Cell Longev. 2021 Jun 18;2021:5551036. (PMID: 34239690)
Bioinformatics. 2012 Aug 1;28(15):2062-3. (PMID: 22718787)
J Clin Oncol. 2020 Sep 10;38(26):2981-2992. (PMID: 32167863)
Cell. 2011 Aug 5;146(3):353-8. (PMID: 21802130)
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. (PMID: 20610543)
Int J Mol Sci. 2023 Jul 12;24(14):. (PMID: 37511115)
Cancer Cell Int. 2019 Feb 26;19:40. (PMID: 30858757)
Technol Cancer Res Treat. 2017 Aug;16(4):435-439. (PMID: 27562869)
Front Biol (Beijing). 2014 Oct;9(5):389-409. (PMID: 25554730)
J Cell Biochem. 2019 Oct;120(10):18465-18477. (PMID: 31168849)
Cancers (Basel). 2022 Oct 22;14(21):. (PMID: 36358604)
Cell Biochem Funct. 2018 Aug;36(6):323-330. (PMID: 30019459)
Cancer Biother Radiopharm. 2021 Aug;36(6):521-533. (PMID: 32412793)
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52. (PMID: 25378301)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
Eur Rev Med Pharmacol Sci. 2022 Feb;26(4):1065-1067. (PMID: 35253158)
Lancet. 2016 Mar 12;387(10023):1094-1108. (PMID: 26354523)
Nucleic Acids Res. 2020 Jan 8;48(D1):D148-D154. (PMID: 31647101)
Nat Rev Genet. 2016 Jan;17(1):47-62. (PMID: 26666209)
Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10354-10362. (PMID: 31841189)
Clin Lab. 2019 Dec 1;65(12):. (PMID: 31850713)
Curr Biol. 2010 Oct 12;20(19):R858-61. (PMID: 20937476)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208)
PLoS One. 2014 Sep 02;9(9):e106397. (PMID: 25181531)
Front Cell Dev Biol. 2021 Jun 24;9:616271. (PMID: 34249899)
Bioengineered. 2021 Dec;12(1):898-913. (PMID: 33682613)
Front Oncol. 2019 May 29;9:448. (PMID: 31192139)
Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095)
Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7419-7429. (PMID: 31539129)
Nat Commun. 2020 Dec 2;11(1):6163. (PMID: 33268787)
Eur J Contracept Reprod Health Care. 2022 Aug;27(4):335-340. (PMID: 35297279)
Cell. 2018 Jan 25;172(3):393-407. (PMID: 29373828)
Pathol Res Pract. 2020 Apr;216(4):152903. (PMID: 32143907)
Cancer Sci. 2018 Jul;109(7):2093-2100. (PMID: 29774630)
Oncogene. 2021 Jan;40(2):277-291. (PMID: 33122827)
Mol Cell. 2019 Sep 5;75(5):982-995.e9. (PMID: 31444106)
Biotechnol Lett. 2017 Oct;39(10):1477-1484. (PMID: 28721581)
Noncoding RNA. 2019 Feb 17;5(1):. (PMID: 30781588)
Biomed Res Int. 2022 Sep 27;2022:4070368. (PMID: 36203482)
Oncotarget. 2017 May 9;8(19):31386-31394. (PMID: 28404901)
Mol Cancer. 2017 Oct 17;16(1):162. (PMID: 29041935)
Elife. 2015 Aug 12;4:. (PMID: 26267216)

Keywords: ceRNA network; diagnosis; lncRNAs; uterine corpus endometrial cancer

0 (RNA, Long Noncoding)
0 (MicroRNAs)
0 (RNA, Messenger)
0 (Biomarkers, Tumor)

Date Created: 20231020 Date Completed: 20231023 Latest Revision: 20231023

20231023

PMC10583181

10.7150/ijms.87430

37859697